{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:27Z","timestamp":1791195687568,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":347,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ijrobp.2025.06.3869","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T11:21:05Z","timestamp":1751023265000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["177Lu-PSMA-617 Single-Photon Emission Computed Tomography\/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles"],"prefix":"10.1016","volume":"123","author":[{"given":"Kellen J.","family":"Fitzpatrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin K.","family":"Mikell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"Roseland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Niedbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery B.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.prro.2022.01.012","article-title":"Lutetium-177 prostate-specific membrane antigen therapy: A practical review","volume":"12","author":"Jia","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0002","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0003","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2967\/jnumed.121.262245","article-title":"Kidney doses in 177Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?","volume":"63","author":"Mix","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0004","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.3390\/cancers13153884","article-title":"Streamlined schemes for dosimetry of 177Lu-labeled PSMA targeting radioligands in therapy of prostate cancer","volume":"13","author":"Kurth","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2967\/jnumed.123.265448","article-title":"Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy","volume":"65","author":"Herrmann","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","article-title":"Dosimetry for 177Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer","volume":"43","author":"Delker","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0007","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.2967\/jnumed.108.053173","article-title":"MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response\u2013implications for radionuclide therapy","volume":"49","author":"Wessels","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0008","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0360-3016(03)01455-X","article-title":"How low is the \u03b1\/\u03b2 ratio for prostate cancer?","volume":"57","author":"Kal","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0009","first-page":"1939","article-title":"Comparison of posttherapy 4- and 24-hour [177Lu]Lu-PSMA SPECT\/CT and pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0010","first-page":"1665","article-title":"A pipeline for automated voxel dosimetry: application in patients with multi-SPECT\/CT imaging after 177Lu-Peptide receptor radionuclide therapy","volume":"63","author":"Dewaraja","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0011","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1109\/TNS.2006.889164","article-title":"Method for fast CT\/SPECT-based 3D Monte Carlo absorbed dose computations in internal emitter therapy","volume":"54","author":"Wilderman","year":"2007","journal-title":"IEEE Trans Nucl Sci"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0012","doi-asserted-by":"crossref","first-page":"6280","DOI":"10.1002\/mp.12586","article-title":"Voxel-based multimodel fitting method for modeling time activity curves in SPECT images","volume":"44","author":"Sarrut","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0013","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1118\/1.2836421","article-title":"Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry","volume":"35","author":"Baechler","year":"2008","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0014","doi-asserted-by":"crossref","first-page":"5310","DOI":"10.1118\/1.3246613","article-title":"AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137","volume":"36","author":"Nath","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0015","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s00259-008-0857-3","article-title":"Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment","volume":"35","author":"Cremonesi","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09553008814551461","article-title":"Does incomplete repair explain the apparent failure of the basic LQ model to predict spinal cord and kidney responses to low doses per fraction?","volume":"54","author":"Thames","year":"1988","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0017","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","article-title":"Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Rosar","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0018","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","article-title":"Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: Comparison of safety, biodistribution, and dosimetry","volume":"63","author":"Schuchardt","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0019","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/diagnostics11030428","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after 177Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"16_suppl","key":"10.1016\/j.ijrobp.2025.06.3869_bib0020","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1200\/JCO.2023.41.16_suppl.5046","article-title":"Tumor dosimetry of [177Lu] Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: Results from the VISION trial sub-study","volume":"41","author":"Krause","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2967\/jnumed.116.178483","article-title":"Radiation dosimetry for 177Lu-PSMA I&T in metastatic castration-resistant prostate cancer: Absorbed dose in normal organs and tumor lesions","volume":"58","author":"Okamoto","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0022","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2967\/jnumed.122.264953","article-title":"Prediction of response to 177Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET\/CT and posttherapeutic tumor-dose evaluation in mCRPC","volume":"64","author":"Hohberg","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0023","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.ijrobp.2010.06.020","article-title":"Biological optimization in volumetric modulated arc radiotherapy for prostate carcinoma","volume":"82","author":"Mihaylov","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0024","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40658-022-00446-2","article-title":"The magnitude of the partial volume effect in SPECT imaging of the kidneys: A phantom study","volume":"9","author":"Grings","year":"2022","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0025","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: Correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0026","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/cancers13030526","article-title":"Early prostate-specific antigen (PSA) change at four weeks of the first-line treatment using abiraterone and enzalutamide could predict early\/primary resistance in metastatic castration-resistant prostate cancer","volume":"13","author":"Uchimoto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0027","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00259-023-06326-w","article-title":"Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"50","author":"Cytawa","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0028","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2025.06.3869_bib0029","first-page":"162","article-title":"Monte Carlo bone marrow dosimetry in radioligand therapy using patient-specific marrow and lesion localization from quantitative 99mTc-sulfur colloid and 177Lu-PSMA-617 SPECT\/CT [abstract]","volume":"64","author":"Peterson","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.06.3869_bib0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-019-0548-z","article-title":"3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT","volume":"9","author":"Gosewisch","year":"2019","journal-title":"EJNMMI Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625045109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625045109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T22:29:45Z","timestamp":1760826585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625045109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0360301625045109"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3869","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"177Lu-PSMA-617 Single-Photon Emission Computed Tomography\/Computed Tomography Dosimetry and Radiobiological Models Demonstrate Decreasing Tumor-to-Kidney Dose Ratio With Successive Cycles","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.06.3869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}